SCHEMBL19957523

SCHEMBL19957523

CNC(=O)NN(c1ccccc1)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
MEN1 O00255 1/20 0.60
ALDH1A1 P00352 6/20 0.47
RECQL P46063 1/20 0.47
NPSR1 Q6W5P4 3/20 0.46
KDM4E B2RXH2 1/20 0.43
L3MBTL1 Q9Y468 3/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 3/20 0.41
ALOX12 P18054 2/20 0.41
MAPT P10636 1/20 0.41
CRHBP P24387 1/20 0.41
HTT P42858 1/20 0.41
CRHR2 Q13324 1/20 0.41
RAB9A P51151 3/20 0.41
GLA P06280 1/20 0.39
TSHR P16473 1/20 0.39
HPGD P15428 2/20 0.39
GPR55 Q9Y2T6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12305501 0.87 KMT2A (0.52) KMT2ASMN1; SMN2MEN1ALDH1A1NPSR1
SCHEMBL28002730 0.79 KMT2A (0.46) KMT2ASMN1; SMN2MEN1ALDH1A1NPSR1
SCHEMBL135871 0.79 KMT2A (0.46) KMT2ASMN1; SMN2MEN1ALDH1A1NPSR1
Acetone SCHEMBL28318232 0.79 KMT2A (0.46) KMT2ASMN1; SMN2MEN1ALDH1A1NPSR1
SCHEMBL4317414 0.78 KMT2A (0.48) KMT2ASMN1; SMN2MEN1ALDH1A1NPSR1
SCHEMBL12305493 0.78 KMT2A (0.53) KMT2ASMN1; SMN2MEN1ALDH1A1NPSR1
SCHEMBL18305859 0.78 KMT2A (0.52) KMT2ASMN1; SMN2MEN1ALDH1A1NPSR1
SCHEMBL10491726 0.78 KMT2A (0.44) KMT2ASMN1; SMN2MEN1ALDH1A1NPSR1
Water SCHEMBL28135297 0.78 KMT2A (0.44) KMT2ASMN1; SMN2MEN1ALDH1A1NPSR1
SCHEMBL27448103 0.77 SMN1; SMN2 (0.41) KMT2ASMN1; SMN2MEN1ALDH1A1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10759749-B2 Therapeutic agent for diabetes JCR PHARMACEUTICALS CO., LTD. (JP) 2020-09-01 US disclosed
US-20190202781-A1 NOVEL THERAPEUTIC AGENT FOR DIABETES JCR PHARMACEUTICALS CO., LTD. (JP) 2019-07-04 US disclosed
EP-3052457-B1 NITROCELLULOSE BASED PROPELLANT COMPOSITION STABILIZED WITH A SUBSTITUTED PHENOL STABILIZER PB CLERMONT SA (BE) 2018-03-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190202781-A1 NOVEL THERAPEUTIC AGENT FOR DIABETES GPR119, IAPP, DPP4 KMT2A 3897/4885SMN1; SMN2 3948/4885MEN1 4253/4885
US-10759749-B2 Therapeutic agent for diabetes GPR119, IAPP, DPP4 KMT2A 3159/4885SMN1; SMN2 3104/4885MEN1 3662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.